Novel Compounds and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 14/894,214, filed Nov 25, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,351,570 | Novel Compounds and Uses Thereof In force · High confidence | Kala Bio, Inc. | In force | High confidence | ||
| US 10,544,151 | Novel Compounds and Uses Thereof In force · High confidence | Kala Bio, Inc. | In force | High confidence | ||
| US 10,954,244 | Novel Compounds and Uses Thereof Lapsed Mar 23, 2025 on the fee record High confidence | Kala Bio, Inc. | Lapsed Mar 23, 2025 on the fee record | High confidence | ||
| US 9,988,386 | Compounds for Treatment of Diseases of Abnormal Angiogenesis or Aberrant Growth Factors and Uses Thereof Lapsed Jun 5, 2026 on the fee record High confidence | Kala Bio, Inc. | Lapsed Jun 5, 2026 on the fee record | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Kala Bio, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.